BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 8607528)

  • 1. Should we treat cholestatic liver disease with cholesterol synthesis inhibitors?
    Schmidt HH; Manns MP
    Am J Gastroenterol; 1996 Feb; 91(2):406-7. PubMed ID: 8607528
    [No Abstract]   [Full Text] [Related]  

  • 2. [Medical treatment of chronic cholestasis: ursodeoxycholic acid].
    Linares Rodríguez A
    Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():24-38. PubMed ID: 11968340
    [No Abstract]   [Full Text] [Related]  

  • 3. [Ursodeoxycholic acid in the treatment of chronic cholestatic liver disease. Documented delay in disease progress inspires hope].
    Olsson R
    Lakartidningen; 2002 Mar; 99(12):1325-30. PubMed ID: 11998165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM; Schrumpf E
    Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The current status of ursodeoxycholate in the treatment of chronic cholestatic liver disease.
    Luketic VA; Sanyal AJ
    Gastroenterologist; 1994 Mar; 2(1):74-9. PubMed ID: 8055235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrates as adjuvant therapy for chronic cholestatic liver disease: its time has come.
    Ghonem NS; Boyer JL
    Hepatology; 2013 May; 57(5):1691-3. PubMed ID: 23174993
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of cholestatic liver diseases].
    Karvonen AL
    Duodecim; 2003; 119(6):533-9. PubMed ID: 12708340
    [No Abstract]   [Full Text] [Related]  

  • 8. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
    Paumgartner G; Beuers U
    Hepatology; 2002 Sep; 36(3):525-31. PubMed ID: 12198643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Autoimmune cholestasis syndrome. Ursodeoxycholic acid is the drug standard].
    Stiefelhagen P
    MMW Fortschr Med; 2007 May; 149(21):49. PubMed ID: 17668736
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic approaches for hepatobiliary disorders with ursodeoxycholic acid and bile-acid derivatives.
    Serfaty L; Poupon R
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S1. PubMed ID: 23141887
    [No Abstract]   [Full Text] [Related]  

  • 11. FXR Agonists: From Bench to Bedside, a Guide for Clinicians.
    Alawad AS; Levy C
    Dig Dis Sci; 2016 Dec; 61(12):3395-3404. PubMed ID: 27734248
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of primary biliary cirrhosis].
    Szalay F
    Orv Hetil; 2003 Sep; 144(36):1787-8. PubMed ID: 14579676
    [No Abstract]   [Full Text] [Related]  

  • 13. Pathogenesis of cholestatic liver disease and therapeutic approaches.
    Hirschfield GM; Heathcote EJ; Gershwin ME
    Gastroenterology; 2010 Nov; 139(5):1481-96. PubMed ID: 20849855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term response of primary biliary cirrhosis (stage I) to therapy with ursodeoxycholic acid.
    Tromm A; May B; Klein CG; Klein R; Fisseler-Eckhoff A; Griga T
    Hepatogastroenterology; 2005; 52(63):753-6. PubMed ID: 15966198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale for therapy with ursodeoxycholic acid in patients with cholestatic liver disease.
    van Erpecum KJ; van de Meeberg PC; van Berge Henegouwen GP
    Neth J Med; 1993 Dec; 43(5-6):233-8. PubMed ID: 8107930
    [TBL] [Abstract][Full Text] [Related]  

  • 16.  The effect of ursodeoxycholic acid in cystic cholangiopathies.
    Lammert F; Méndez-Sánchez N
    Ann Hepatol; 2016 Nov-Dec 2016; 15(6):949-950. PubMed ID: 27740534
    [No Abstract]   [Full Text] [Related]  

  • 17. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy.
    Babatin MA; Sanai FM; Swain MG
    Aliment Pharmacol Ther; 2006 Sep; 24(5):813-20. PubMed ID: 16918885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents.
    Silveira MG; Lindor KD
    Clin Liver Dis; 2008 May; 12(2):425-43; x-xi. PubMed ID: 18456189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the therapy of cholestatic liver disease.
    Roda E; Parini P; Bazzoli F; Mazzella G; Festi D; Aldini R
    Hepatogastroenterology; 1992 Feb; 39 Suppl 1():53-5. PubMed ID: 1577396
    [No Abstract]   [Full Text] [Related]  

  • 20. Ursodeoxycholic acid and long-term survival in primary biliary cirrhosis.
    Levy C; Angulo P
    Am J Gastroenterol; 2004 Feb; 99(2):269-70. PubMed ID: 15046216
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.